Trials / Active Not Recruiting
Active Not RecruitingNCT05023382
A Study of Teduglutide in Japanese People With Short Bowel Syndrome
Special Drug Use Investigation of Revestive Subcutaneous Injection 3.8 mg (All-case Surveillance)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The main aims of this study are to check for side effects from treatment with teduglutide (Revestive) and how well teduglutide controls symptoms of short bowel syndrome. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. During the study, participants with short bowel syndrome will receive an injection of teduglutide just under the skin (subcutaneous) according to their clinic's standard practice. The study doctors will check for side effects from teduglutide for 36 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teduglutide | Teduglutide 0.05 mg/kg SC injection |
Timeline
- Start date
- 2021-09-01
- Primary completion
- 2026-07-31
- Completion
- 2026-07-31
- First posted
- 2021-08-26
- Last updated
- 2026-04-13
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05023382. Inclusion in this directory is not an endorsement.